FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to a chimeric antigen receptor. Said chimeric antigen receptor specifically recognizes ganglioside GD2 and contains a GD2-binding domain containing CDR1-CDR3 of the heavy chain with sequences SEQ ID NO: 1–3, respectively, as well as light chain CDR1-CDR3 with sequences SEQ ID NO: 9–11, respectively. Present invention also relates to a polynucleotide coding said chimeric antigen receptor, a cell, including a T-cell or NK-cell containing said polynucleotide, as well as a pharmaceutical composition containing an effective amount of T-cells or NK-cells.
EFFECT: invention provides high cytotoxic activity and therapeutic efficacy in treating cancer, which is aimed at GD2 at the molecular level.
9 cl, 27 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| ANTIGEN-BINDING PROTEIN RECOGNIZING PEPTIDE ORIGINATING FROM MAGE-A4 | 2018 |
|
RU2777074C2 |
| CHIMERIC ANTIGEN RECEPTORS | 2015 |
|
RU2745705C2 |
| THERAPEUTIC AGENTS | 2016 |
|
RU2747733C1 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
